Cite
TCT-638 Diabetes Mellitus Confers Worse Clinical Outcomes at 1 Year Compared to Non–Diabetes Mellitus in an All-Comer Population Implanted With Biodegradable Polymer Everolimus-Eluting Stents.
MLA
Sim, Hui Wen, et al. “TCT-638 Diabetes Mellitus Confers Worse Clinical Outcomes at 1 Year Compared to Non–Diabetes Mellitus in an All-Comer Population Implanted With Biodegradable Polymer Everolimus-Eluting Stents.” Journal of the American College of Cardiology (JACC), vol. 74, no. 13, Oct. 2019, p. B626. EBSCOhost, https://doi.org/10.1016/j.jacc.2019.08.756.
APA
Sim, H. W., He, S., Chan, M., Lee, R., Tan, H. C., Low, A., Tay, E., Chan, K. H., Loh, P. H., & Loh, J. (2019). TCT-638 Diabetes Mellitus Confers Worse Clinical Outcomes at 1 Year Compared to Non–Diabetes Mellitus in an All-Comer Population Implanted With Biodegradable Polymer Everolimus-Eluting Stents. Journal of the American College of Cardiology (JACC), 74(13), B626. https://doi.org/10.1016/j.jacc.2019.08.756
Chicago
Sim, Hui Wen, Sen He, Mark Chan, Ronald Lee, Huay Cheem Tan, Adrian Low, Edgar Tay, Koo Hui Chan, Poay Huan Loh, and Joshua Loh. 2019. “TCT-638 Diabetes Mellitus Confers Worse Clinical Outcomes at 1 Year Compared to Non–Diabetes Mellitus in an All-Comer Population Implanted With Biodegradable Polymer Everolimus-Eluting Stents.” Journal of the American College of Cardiology (JACC) 74 (13): B626. doi:10.1016/j.jacc.2019.08.756.